Challenges and Opportunities of TKIs in the Treatment of NSCLC Patients With Uncommon Mutations

Challenges and Opportunities of TKIs in the Treatment of NSCLC Patients With Uncommon Mutations PDF book is popular Medical book written by Shi-Yong Sun. The book was released by Frontiers Media SA on 2022-08-30 with total hardcover pages 109. Fast download link is given in this page, you could read Challenges and Opportunities of TKIs in the Treatment of NSCLC Patients With Uncommon Mutations by Shi-Yong Sun in PDF, epub and kindle directly from your devices.

Challenges and Opportunities of TKIs in the Treatment of NSCLC Patients With Uncommon Mutations

Released on 2022-08-30 by Shi-Yong Sun

Challenges and Opportunities of TKIs in the Treatment of NSCLC Patients With Uncommon Mutations Book Detail
Author : Shi-Yong Sun
Release Date : 2022-08-30
Publisher : Frontiers Media SA
Genre : Medical
Pages : 109
ISBN 13 : 288976866X
File Size : 80,80 MB

DOWNLOAD BOOK

EGFR TKI PET/CT in Advanced Stage Non-small Cell Lung Cancer Patients

File Size : 19,19 MB
Total View : 303 Views
DOWNLOAD

An overview of biomarker development is provided in chapter 2.PET tracer-based biomarkers can be used to monitor different biological or clinical metrics. A cli

Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs

File Size : 31,31 MB
Total View : 5372 Views
DOWNLOAD

Lung cancer still remains a challenging disease with a higher mortality rate in comparison to other cancers. The discovery of oncogene addicted tumours and targ

IASLC Atlas of ALK and ROS1 Testing in Lung Cancer

File Size : 93,93 MB
Total View : 5947 Views
DOWNLOAD

The IASLC Atlas of ALK and ROS1 Testing in Lung Cancer is a resource designed to help pathologists, laboratory scientists, and practicing physicians better unde

Targeted Therapies for Lung Cancer

File Size : 24,24 MB
Total View : 1453 Views
DOWNLOAD

This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is